Enfuvirtide Acetate (T-20)
Alias:Fuzeon
Sequência:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas Não. : 159519-65-0
Fórmula Molecular : C204H301N51O64
Peso molecular : 4492
Pureza (HPLC) : 98.0%min.
Aparência : White to off-white amorphous solid
Impureza Única (HPLC) : 0.5%máx.
Composição de aminoácidos : ±10% do teórico
Conteúdo Peptídico (N%) : ≥80,0%
Conteúdo de água (Carlos Fischer) : ≤8,0%
TrifluoroAcetate Content(HPIC) : ≤12,0%
EM (ESI) : Consistente
Balanço de Massa : 95.0~105,0%
Nota : Grau Farmacêutico
Armazenar: Closed, below 2 ~ 8℃ preservation
Uso : Treatment option for patients suffering from HIV/AIDS.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (POUSADA) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
